This series on “Radiotherapy for Brain Metastases from Lung Cancer” is edited by Prof. Lucyna Kepka from the Department of radiotherapy, Miitary Institute of Medicine, Warsaw, Poland.
All aforementioned considerations relate to the patients with preserved performance status who may benefit from the progress in the management of lung cancer. However, among patients with brain metastases from lung cancer, there is a significant proportion of patients with poor performance status, for whom WBRT has no benefit over the use of steroids alone. These patients should benefit from the early introduction of all measures of palliative care without radiotherapy, because such an approach improves the quality of life, especially in patients with lung cancer.
Treatment of brain metastases from lung cancer: challenging the historical nihilism concerning prognosis
Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer
Hippocampal avoidance in prophylactic cranial irradiation for small cell lung cancer: benefits and pitfalls
WBRT for brain metastases from non-small cell lung cancer: for whom and when?—Contemporary point of view
Supportive care for patients with brain metastases from lung cancer
Radiotherapy for brain metastases from small-cell lung cancer in distinct clinical indications and scenarios
Prophylactic cranial irradiation in non-small cell lung cancer: evidence and future development
Local ablative therapy of brain metastasis from non-small cell lung cancer: benefits and limitations
Management of brain metastases in elderly patients with lung cancer
Radiotherapy of brain metastasis from lung cancer in limited resource settings
Combination of immunotherapy and radiotherapy in the treatment of brain metastases from non-small cell lung cancer
The series “Radiotherapy for Brain Metastases from Lung Cancer” was commissioned by the editorial office, Journal of Thoracic Disease without any funding or sponsorship. Lucyna Kepka is serving as the unpaid Guest Editor for the series.